Peptides

Abaloparatide

A bone-forming medicine with fracture evidence in postmenopausal osteoporosis; the indication in men is supported by bone-density outcomes.

Randomized fracture trial in postmenopausal osteoporosis; population limits

Also known as: Tymlos · PTHrP analogue

Abaloparatide molecular structure — Structure reference · C174H300N56O49

Practical use

Clinical context and evidence interpretation

Prepare the right history: Bring prior low-trauma fractures, bone-density reports with dates, kidney-stone history and previous osteoporosis treatment to a clinical review.
Compare the actual endpoint: Ask whether a quoted percentage means relative fracture reduction, absolute fracture reduction or a change in bone density.
Make follow-up explicit: Ask the treating team how response and adverse effects will be reviewed, and how the longer-term bone-care plan fits together.

ACTIVE: fracture prevention over 18 months

US prescribing information; checked October 1, 2026

Overview

Abaloparatide is a parathyroid hormone-related peptide analogue that activates the PTH1 receptor and stimulates bone formation. US Tymlos labeling covers postmenopausal osteoporosis at high fracture risk and increasing bone density in men at high fracture risk. It is a different molecule from teriparatide.

Risks and limitations

Dizziness, palpitations, nausea, excess blood or urine calcium and kidney-stone concerns matter. Label precautions include bone cancers, skeletal radiation and other conditions that raise osteosarcoma risk. Serious allergy is possible; breathing difficulty or facial swelling needs emergency care.

How to read this

For a reader comparing bone medicines, the useful distinction is fewer fractures versus a higher bone-density measurement. A stronger scan result is valuable evidence, but it does not by itself quantify fracture prevention in every population.

Research explained

ACTIVE: fracture prevention over 18 months

Who was studied

2,463 postmenopausal women with osteoporosis, average age 69, randomized to abaloparatide, placebo or open-label teriparatide; 1,901 completed the study.

What was found

Abaloparatide reduced new vertebral and nonvertebral fractures versus placebo. The primary report found hypercalcemia in 3.4% with abaloparatide versus 6.4% with teriparatide. The FDA label reports new vertebral fractures in 0.6% versus 4.2% with placebo.

What it cannot establish

The blinded primary comparison was abaloparatide versus placebo. The study does not establish that abaloparatide is the best treatment for every patient or that these fracture estimates apply to younger healthy men.

Read the original study

Put the absolute effect beside the headline

The label’s 0.6% versus 4.2% vertebral-fracture figures correspond to approximately 3.6 fewer fractures per 100 comparable patients over 18 months. This is an absolute difference, not a prediction for an individual.

Supporting source